These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

659 related articles for article (PubMed ID: 25756514)

  • 1. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.
    Liu R; Guo CX; Zhou HH
    Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Network-based approach to identify prognosis-related genes in tamoxifen-treated patients with estrogen receptor-positive breast cancer.
    Wang Y; Gong X; Zhang Y
    Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34406386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer.
    Alfarsi LH; El-Ansari R; Craze ML; Masisi BK; Mohammed OJ; Ellis IO; Rakha EA; Green AR
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance.
    Gao T; Han Y; Yu L; Ao S; Li Z; Ji J
    PLoS One; 2014; 9(3):e91771. PubMed ID: 24622579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.
    Bianchini G; Pusztai L; Karn T; Iwamoto T; Rody A; Kelly C; Müller V; Schmidt S; Qi Y; Holtrich U; Becker S; Santarpia L; Fasolo A; Del Conte G; Zambetti M; Sotiriou C; Haibe-Kains B; Symmans WF; Gianni L
    Breast Cancer Res; 2013; 15(5):R86. PubMed ID: 24060333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlating transcriptional networks with pathological complete response following neoadjuvant chemotherapy for breast cancer.
    Liu R; Lv QL; Yu J; Hu L; Zhang LH; Cheng Y; Zhou HH
    Breast Cancer Res Treat; 2015 Jun; 151(3):607-18. PubMed ID: 25981901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer.
    Rudolph M; Sizemore ST; Lu Y; Teng KY; Basree MM; Reinbolt R; Timmers CD; Leone G; Ostrowski MC; Majumder S; Ramaswamy B
    Breast Cancer Res Treat; 2018 Jun; 169(3):457-467. PubMed ID: 29464534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of hub genes in AR-induced tamoxifen resistance in breast cancer based on weighted gene co-expression network analysis.
    Lu C; Yang Y; Lingmei L; Qiujuan H; Qianru G; Lisha Q; Wenfeng C; Yun N; Peisen Z
    Breast Cancer Res Treat; 2023 Jan; 197(1):71-82. PubMed ID: 36334189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.
    Soleimani Dodaran M; Borgoni S; Sofyalı E; Verschure PJ; Wiemann S; Moerland PD; van Kampen AHC
    BMC Cancer; 2020 Jul; 20(1):676. PubMed ID: 32684154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
    Wu JR; Zhao Y; Zhou XP; Qin X
    Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
    Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
    Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.
    Habashy HO; Powe DG; Staka CM; Rakha EA; Ball G; Green AR; Aleskandarany M; Paish EC; Douglas Macmillan R; Nicholson RI; Ellis IO; Gee JM
    Breast Cancer Res Treat; 2010 Jan; 119(2):283-93. PubMed ID: 19238537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
    Bergamaschi A; Christensen BL; Katzenellenbogen BS
    Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression.
    Lv Q; Guan S; Zhu M; Huang H; Wu J; Dai X
    Technol Cancer Res Treat; 2021; 20():15330338211004935. PubMed ID: 33783288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EPRS is a critical regulator of cell proliferation and estrogen signaling in ER+ breast cancer.
    Katsyv I; Wang M; Song WM; Zhou X; Zhao Y; Park S; Zhu J; Zhang B; Irie HY
    Oncotarget; 2016 Oct; 7(43):69592-69605. PubMed ID: 27612429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer.
    Madhavan S; Gusev Y; Singh S; Riggins RB
    J Exp Clin Cancer Res; 2015 May; 34(1):45. PubMed ID: 25971350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
    Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High GINS2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammary cancer stem cells in breast cancer patients.
    Zheng M; Zhou Y; Yang X; Tang J; Wei D; Zhang Y; Jiang JL; Chen ZN; Zhu P
    Breast Cancer Res Treat; 2014 Nov; 148(2):423-36. PubMed ID: 25348432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR is a Therapeutic Target in Hormone Receptor-Positive Breast Cancer.
    Jeong Y; Bae SY; You D; Jung SP; Choi HJ; Kim I; Lee SK; Yu J; Kim SW; Lee JE; Kim S; Nam SJ
    Cell Physiol Biochem; 2019; 53(5):805-819. PubMed ID: 31670920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.